Why Is ULTRAGENYX PHARMACEU (RARE) Stock Up Today?
By the Top Tier Newswire AI Desk · October 7, 2026 at 10:34 AM ET · reviewed against 5 wire stories
ULTRAGENYX PHARMACEU (RARE) is up +5.05% in the latest session. Our newswire has captured 5 stories on RARE across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 50/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why RARE stock is up today
Ultragenyx Pharmaceutical (RARE) rose 5.05% to $15.19 in morning trading on October 7, 2026, following the company’s announcement of a $210 million deal to sell an FDA priority review voucher. The move reflects investor interest in the monetization of a non-core asset and signals the company’s ability to generate near-term liquidity. The stock opened lower but reversed sharply to post a new session high shortly after 10:30 AM ET.
What Happened
Ultragenyx announced on October 6, 2026, that it had entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher tied to its recent Genglycos approval. The voucher allows the holder to expedite the FDA review of a future drug application. The $210 million sale is expected to provide the company with immediate cash flow, which may be used to support ongoing operations or future development programs. The transaction was disclosed in a Form 8-K filed with the SEC on October 7, 2026.
Retail traders and institutional observers have highlighted the transaction as a significant development for a company with a market cap of $1.4 billion and a history of unprofitability. The stock’s performance was also supported by recent analyst activity, including raised price targets from Evercore ISI Group, Barclays, and Morgan Stanley.
What The Data Shows
The stock opened at $14.31, a 1.0% gap down from the prior close, but quickly reversed to reach a high of $15.21. Trading volume stood at 0.9 million shares by the close of the morning session, representing 0.2 times the 3-month daily average. The stock has traded in a 52-week range of $12.73 to $39.89, with today’s move pushing it closer to the upper end of that range. Over the last 8 sessions, the stock has risen 1.4% from $14.26 to $14.46. The company reported a TTM revenue increase of 17.5% but remains unprofitable with a net margin of -81.7%.
What To Watch
The stock is set to continue its session with a focus on how the market digests the cash inflow from the voucher sale. Investors may also monitor the company’s ability to execute on its broader pipeline, including its gene therapy for MPS IIIA, which recently cleared EMA validation.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
RARE · today's session (5-min) · +2.25% vs prior close · updated 3:33 PM ETAI sentiment, last 36h · averaged over 5 stories · 50/100 neutral
The headlines behind the move
Story flow · 5 stories on the wire, last 36h · hover or tap a dot for the headline
5h agoSeeking AlphaBULLISH 59General
Ultragenyx to sell FDA priority review voucher for $210M
Ultragenyx Pharmaceutical (RARE) stock gains as the company inks a $210M deal to sell an FDA priority review voucher tied to recent Genglycos approval. Read more here.
6h agoTipRanksBULLISH 59General
Ultragenyx Monetizes FDA Priority Review Voucher Asset
Ultragenyx Pharmaceutical ( ($RARE) ) has issued an update. On October 6, 2026, Ultragenyx Pharmaceutical Inc. entered into an asset purchase agreement to sell a Ra...
6h agoSEC 8-KNEUTRAL 50General
Ultragenyx Pharmaceutical Inc. (RARE) files 8-K
Filed: 2026-10-07 AccNo: 0001193125-26-416251 Size: 149 KB Item 1.01: Entry into a Material Definitive Agreement
6h agoThe FlyBEARISH 24General
Ultragenyx to sell Rare Pediatric Disease Priority Review Voucher for $210M
7h agoBusiness InsiderBULLISH 58General
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
NOVATO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →